RICHMOND, British Columbia, Dec. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX.OB - News)
announced today that its wholly owned subsidiary, OncoPet(TM)
Diagnostics, Inc., has executed an agreement for the distribution of the
OncoPet Sample Collection Kit for canine cancer diagnosis with Butler
Schein(TM) Animal Health. Butler Schein Animal Health, a division of
Henry Schein (Nasdaq:HSIC - News), is the leading companion animal health distribution company in the U.S.
According to the agreement, Butler Schein is allowed to purchase the
OncoPet Sample Collection Kit from OncoPet Diagnostics to resell to
their vast network of veterinary professionals in the United States. The
Company has sent Webster Veterinary notice of termination of its
previous distribution agreement.
"We are extremely satisfied to have completed a definitive distribution
agreement for sales of the OncoPet Sample Collection Kit with Butler
Schein," stated Dr. Paul D. Slowey, President of BioCurex. "With the
largest animal health distribution company in the U.S. now under
agreement with OncoPet, we are confident that our products and services
will be comprehensively represented to animal health professionals
throughout the largest veterinary market in the world.
Dr. Ricardo Moro, OncoPet's President and BioCurex's CEO added, "It is
important to stress the significance of this agreement because the
largest distributor of veterinary products in the U.S. knows what sells
well and how to make money with the products they carry. Their
confidence in the OncoPet RECAF test is a huge endorsement and a clear
indication of its commercial potential. The sales force of this company
is in the hundreds and our facilities are ready to process any orders
resulting from their efforts.
About Butler Schein
Butler Schein Animal Health, a division of Henry Schein, is the leading
companion animal health distribution company in the U.S.
Headquartered in Dublin, Ohio, the company employs approximately 900
team members, including 300 field sales representatives and 200
telesales and customer support representatives. With 17 strategically
positioned, state-of-the-art distribution facilities and 12 inside sales
centers nationwide, Butler-Schein maintains a greater than 98 percent
order-fill ratio, accomplishing its mission of providing the right
product, at the right place and at the right time.
Partnering with over 400 of the leading animal health manufacturers in
the world, Butler-Schein is positioned to bring the broadest selection
of veterinary products and strategic business solutions to over 26,000
veterinary professionals nationwide.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products
based on patented and proprietary technology in the area of cancer
diagnostics. The technology identifies a universal cancer marker known
as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in
significant levels on healthy cells or benign tumor cells. It is the
receptor for alpha-fetoprotein and is classified as an oncofetal antigen
due to its presence on both fetal and malignant tissues. This
characteristic makes RECAF a more accurate indicator of cancer than most
current tumor markers.
BioCurex is commercializing its technology through licensing
arrangements with companies that develop and market diagnostic tests for
the large automated clinical laboratory setting, through development
and marketing of non-automated clinical laboratory tests, through
development of rapid, point-of-care test formats, and through marketing
of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:
ABT -
News) and with Alere (NYSE:
ALR -
News), formerly Inverness Medical Innovations (NYSE:IMA).
For further information on these agreements visit:
http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt.
For more information about the Company, please visit
www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit:
www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in
any form that contravenes the Communication Act and will not be
responsible for unsolicited massive distribution of this material by
e-mail or facsimile by unauthorized parties. Statements in this press
release, which are not historical facts, are "forward-looking
statements'' within the meaning given to that term in the Private
Securities Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. Since these statements, such as forecasts of future sales,
involve risks and uncertainties and are subject to change at any time,
the Company's actual results could differ materially from expected
results.
Contact:
Investor Relations Contact:
DC Consulting
(407) 792-3333
investorinfo@dcconsultingllc.com
